Hospital readmission program not associated with increased risk of death in patients
Detailed analysis of today’s statistics by alcohol addiction treatment experts UKAT ( www.ukat.co.uk ) shows that the biggest reason for admission into hospital was for Cardiovascular disease, accounting for 645,070 (51%) of all admissions.
17% (220,730) of all admissions were for mental and behavioral disorders due to alcohol, conditions which include acute intoxication, harmful use of alcohol, dependence to alcohol and withdrawal from alcohol.
Other conditions for hospital admission due to alcohol include breast cancer, alcohol poisoning, and alcoholic liver disease.
Nuno Albuquerque, Group Treatment Lead at addiction firm UKAT comments:
This country’s problem with alcohol is a ticking time bomb about to explode. The NHS is crippling under pressures directly attributable to the misuse of alcohol; what will it take to make the Government sit up, listen and take effective action? Why do we still not have an Alcohol-specific Strategy, as promised back in 2018? It is a huge problem and one that needs immediately addressed as a matter of urgency.”
When it came to deaths in 2018, 5,698 people died due to drink – 2% lower than in 2017 but a 7% rise in ten years.
The NHS report also shows how many prescribed drugs were dispensed last year to tackle the country’s problem with alcohol- 170,000 prescribed drugs issued in 2018, 27% more than in 2008.
The North of England dispensed 68,000 prescription items to combat alcohol misuse which accounted for 46% of all items. London dispensed the lowest number, just 12,000.
The NHS is being forced into a corner when it comes to tackling alcohol misuse. GP’s prescribing drugs like Acamprosate Calcium, Disulfiram and Nalmefene will only pause the problem, not solve it.
Taking this sticky-plaster approach is also a false economy, costing the NHS an eye-watering £4.32million last year alone.” Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology